Mark Matson
Nephrology · St. Paul, MNNPI 1447343330
Payments from drug & device makers
What this record shows
That places this record below the midpoint for nephrology clinicians in MN, where the typical reported total is $121.
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$6,324,897in research payments, 2019–2025
Across 103 payments — averaging $61,407 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$2.9M
- Sanofi US Services Inc.$2.2M
- Merck$566K
- Pfizer$446K
- Roche Diagnostics Operations, Inc.$126K
- Kowa Research Institute, Inc.$82K
- plus $39K from 4 others
How this compares
$0 in reported general payments places this provider in the 20th percentile of 208 nephrology providers in Minnesota.
Other nephrology in St. Paul
- Neera DahlRochester$102K
- Fernando FervenzaRochester$102K
- Kirsten JohansenMinneapolis$101K
- Jeffrey KohenMinneapolis$56K
- James WetmoreMinneapolis$48K
- Nelson LeungRochester$32K
- John LieskeRochester$31K
- Leticia RolonRochester$30K
- Prince SinghDuluth$26K
- Nattawat KlomjitRochester$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.